Roche Launches Two New Antibodies to Identify Key Clinical Mutations
Thursday, February 23, 2023
Roche announced the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer. The IDH1 R132H and ATRX antibodies are the latest additions to Roche’s neuropathology portfolio, containing 29 biomarkers.
IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody detects the IDH1 R132H mutation in adult-type gliomas and in acute myeloid leukaemia (AML). When present, IDH1 R132H is associated with a relatively favourable prognosis and is important in patient stratification for clinical trials. IDH1 R132H immunohistochemistry is recommended by all major glioma clinical practise guidelines as the initial IDH testing modality. ATRX Rabbit Polyclonal Antibody detects a mutation in the ATRX gene, providing significant diagnostic and prognostic information to clinicians. ATRX testing is considered “desirable” by the World Health Organisation for IDH-mutant gliomas.
The two IDH1 and ATRX assays are optimised and fully-automated on the BenchMark series of instruments. These two tests are now available in the United States. They are likely to become available in other non-CE markets later this year and in countries adopting the CE mark in 2024.
